REFERENCES
- Greenfield, R. S., T. Kaneko, A. Daues, M. A. Edson, K. A. Fitzgerald, L. J. Olech, A. Grattan, G. L. Spitalny, and G. R. Braslawsky. 1990. In vitro eval- uation of Adriamycin immunoconjugate s synthesize d using an acid-sensitive hydrazon e linker. Cancer Res. 50:6600– 6607.
- Hillman, G. G., J. Droz, and G. H. Haas. 1994. Experimental animal model s for the study of therapeutic approache s in renal cell carcinoma. In Vivo 8:77– 80.
- Kratz, F., M. Hartmann, B. K. Keppler, and L. Messori. 1994. The bind- ing properties of two antitumor ruthenium(III) complexe s to apotransferrin. J. Biol. Chem. 269:2581 – 2588.
- Kratz, F., U. Beyer, M. KruÈger, P. Schumacher, H. Zahn, T. Roth, H. H. Fiebig, and C. Unger. 1997a. Synthesis of new maleimide derivative s of daunorubici n and biological activity of acid labile transferrin conjugates. Biorg. Med. Chem. Lett. 7:617– 622.
- Kratz, F., I. Fichtner, U. Beyer, P. Schumacher, T. Roth, H. H. Fiebig, and C. Unger. 1997b. Antitumour activity of acid labile transferrin and albumin doxorubici n conjugate s in in vitro and in vivo human tumor xenograf t models. Eur. J. Cancer 33(suppl. 8): S175.
- Kratz, F., U. Beyer, P. Collery, F. Lechenault, A. Cazabat, P. Schumacher, U. Falken, and C. Unger. 1998a. Preparation, characterizatio n and in vitro eficacy of albumin conjugate s of doxorubicin. Biol. Pharm. Bull. 21:56– 61.
- Kratz, F., U. Beyer, T. Roth, N. Tarasova, P. Collery, F. Lechenault, A. Cazabat, P. Schumacher, C. Unger, and U. Falken. 1998b. Transferrin conjugate s of doxorubicin: Synthesis, characterization, cellular uptake, and in vitro eficacy. J. Pharm. Sci. 87:338– 346.
- Kratz, F., T. Roth, I. Fichtner, H. H. Fiebig, and C. Unger. 1998c. Develop- ment of antitumor protein and polymer conjugate s using in vitro and in vivo tumor xenograf t models. In Relevance of tumor models for anticance r drug development, Contribution to oncology, 27 ed. H. H. Fiebig. Basel: Karger Verlag. Maeda, H., and Y. Matsumura. 1989. Tumoritropi c and lymphotropi c principles of macromolecula r prodrugs. Crit. Rev. Ther. Drug Carrier Sys. 6:193– 210.
- Mancilla-Jimenez, R. 1976. Papillary renal cell carcinoma: A clinical, radiolog- ical and pathologica l study of 34 cases. Cancer 38:2466 – 2469.
- Matsumura, Y., and H. Maeda. 1986. A new concep t for macromolecula r ther- apeutics in cancer chemotherapy: Mechanism of tumoritropic accumulatio n of proteins of the antitumor agent smancs. Cancer Res. 46:6387– 6392.
- Salup, R. R., and R. H. Wiltrout. 1986. Adjuvant immunotherapy of estab- lished murine renal cancer by interleukin 2 stimulated cytotoxic lymphocytes. Cancer Res. 46:3358 – 3363.
- Sands, H., P. L. Jones, A. S. Shah, D. Palme, R. L. Vessella, and B. M. Gallagher. 1988. Correlation of vascular permeability and blood ¯ow with monoclona l antibody uptake by human clouse and renal cell xenografts. Cancer Res. 48:188–193.
- Sayers, T. J., T. A. Wiltrout, McCormick K., Husted C., and Wiltrout R. H.. 1990. Antitumor effects of interferon and cinterferon on a murine renal cancer (Renca) in vitro and in vivo.Cancer Res. 50 5414–5420.
- Schuler, J., H. H. Fiebig, E. A. Sausville, and A. M. Burger. 1997. Characteriza- tion of vascular permeability in human tumor xenografts ÐIdentification of suitable tumor models to evaluate polymer conjugates. Int. Symp. Relevance of Tumor Models for Anticancer Drug Developmen t, p. 6, 15– 17 October, Tumor Biology Center, Freiburg, FRG.
- Sinn, H., H. H. Schrenk, A. Friedrich, U. Schilling, and W. Maier-Borst. 1990. Design of compound s having an enhanced tumour uptake, using serum albu- min as a carrier. Part 1. Nucl. Med. Biol. 17(Int. J. Rad. Appl. Instrum. B):819– 827.
- Takakura, Y., T. Fujita, M. Hashida, and H. Sezaki. 1990. Disposition charac- teristics of macromolecule s in tumor-bearin g mice. Pharm. Res. 7:339– 346.